Pharvaris (PHVS) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChart

PHVS Stock Forecast


Pharvaris (PHVS) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $39.67, with a high of $50.00 and a low of $27.00. This represents a 184.58% increase from the last price of $13.94.

$10 $18 $26 $34 $42 $50 High: $50 Avg: $39.67 Low: $27 Last Closed Price: $13.94

PHVS Stock Rating


Pharvaris stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

PHVS Price Target Upside V Benchmarks


TypeNameUpside
StockPharvaris184.58%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends


1M3M12M
# Anlaysts--1
Avg Price Target--$42.00
Last Closing Price$13.94$13.94$13.94
Upside/Downside--201.29%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2524--17
Mar, 2524--17
Feb, 2524--17
Jan, 2524--17
Dec, 2424--17
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 14, 2024Justin KimOppenheimer$42.00$19.73112.87%201.29%
Apr 11, 2024Jonathan WollebenJMP Securities$50.00$22.27124.52%258.68%
Sep 25, 2023Laura ChicoWedbush$27.00$20.6730.62%93.69%
Jan 11, 2023JMP Securities$23.00$10.32122.87%64.99%
Dec 09, 2022JMP Securities$22.00$11.4691.97%57.82%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024OppenheimerOutperformOutperformhold
Sep 06, 2024OppenheimerOutperformOutperformhold
Jul 03, 2024OppenheimerOutperformOutperformhold
Aug 15, 2023Morgan StanleyOverweightupgrade
Feb 03, 2023SVB LeerinkOutperformOutperformhold
Jan 11, 2023JMP SecuritiesMarket OutperformMarket Outperformhold
Dec 09, 2022JMP SecuritiesMarket OutperformMarket Outperformhold

Financial Forecast


EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.57-----
Avg Forecast$-2.45$-2.71$-3.14$-3.05$-2.48$-0.31
High Forecast$-1.95$-2.47$-3.01$-2.86$-1.96$-0.31
Low Forecast$-2.69$-3.07$-3.23$-3.19$-2.96$-0.31
Surprise %4.90%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$7.56M$43.69M$219.25M
High Forecast---$7.56M$45.17M$219.25M
Low Forecast---$7.56M$42.20M$219.25M
Surprise %------

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-98.81M-----
Avg Forecast$-91.67M$-106.40M$-119.81M$-116.16M$-94.49M$-11.88M
High Forecast$-74.81M$-94.88M$-115.47M$-109.98M$-75.27M$-11.88M
Low Forecast$-103.42M$-117.93M$-124.14M$-122.33M$-113.71M$-11.88M
Surprise %7.79%-----

PHVS Forecast FAQ


Is Pharvaris stock a buy?

Pharvaris stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Pharvaris is a favorable investment for most analysts.

What is Pharvaris's price target?

Pharvaris's price target, set by 7 Wall Street analysts, averages $39.67 over the next 12 months. The price target range spans from $27 at the low end to $50 at the high end, suggesting a potential 184.58% change from the previous closing price of $13.94.

How does Pharvaris stock forecast compare to its benchmarks?

Pharvaris's stock forecast shows a 184.58% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Pharvaris over the past three months?

  • April 2025: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • March 2025: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 14.29% Strong Sell.

What is Pharvaris’s EPS forecast?

Pharvaris's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.71, marking a 5.45% increase from the reported $-2.57 in 2023. Estimates for the following years are $-3.14 in 2025, $-3.05 in 2026, $-2.48 in 2027, and $-0.31 in 2028.

What is Pharvaris’s revenue forecast?

Pharvaris's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $7.56M for 2026, $43.69M for 2027, and $219.25M for 2028.

What is Pharvaris’s net income forecast?

Pharvaris's net income forecast for the fiscal year ending in December 2024 stands at $-106M, representing an 7.69% increase from the reported $-98.807M in 2023. Projections indicate $-120M in 2025, $-116M in 2026, $-94.492M in 2027, and $-11.878M in 2028.